ClinicalTrials.gg
CompletedNCT03451084Updated Jul 6, 2021Results posted

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

A Phase 2 interventional study of ASLAN003 in Acute Myeloid Leukemia, sponsored by ASLAN Pharmaceuticals. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by ASLAN Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 148 studies in Leukemia, Myeloid, Acute with a site in Australia — 23 open to participants now, 45 under way, 17 of them phase 3. Leukemia, Myeloid, Acute · Australia.

Enrollment
124th of 144
24 · median 108
Started
2018
with 14 others
Phase 2
19 of 148
2 open now
Registered
72nd of 148
by date

Among the 148 studies in Leukemia, Myeloid, Acute with a site in Australia, this one is the 124th largest by enrollment of the 144 interventional ones that give a count, is one of 15 that started in 2018, is one of 19 in phase 2, and was the 72nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

23 of the 148 studies in Leukemia, Myeloid, Acute with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Leukemia, Myeloid, Acute with a site in Australia, or all of them as a file.
02

Study summary

ASLAN003-003 is a multi-center, Phase IIA study to evalute the efficacy of ASLAN003 in AML patients who are ineligible for standard treatment with an expansion cohort in relapsed/refractory patients, and to determine the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.

Read the detailed description

ASLAN003-003 is a multi-center, Phase IIA study to determine the optimum dose of ASLAN003 based on the safety, efficacy, and tolerability of varying doses of ASLAN003 (100 mg QD, 200 mg QD, 100 mg BID, and possibly 200 mg BID) administered to AML subjects daily for a continuous 28-day treatment cycle until disease relapse, disease progression, unacceptable toxicity, or withdrawal of consent.

The study has 2 parts and plans to enroll a total of 44 to 56 patients with 18 to 24 patients in Part 1 and 26 to 32 patients in Part 2 (comprising Parts 2A and 2B). The Overall Complete Remission Rate will be evaluated in AML patients not eligible for standard treatment (Part 1) and in relapsed and refractory AML patients (Part 2A) using the optimum dose of ASLAN003 established in Part 1 of the study. In Part 2B of the study, the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options will be determined.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • AML, ASLAN, DHODH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are of or older than 18 years old in the United States or are of or older than the legal age in the respective countries at the time when written is obtained
  2. Patients who are able to understand and willing to sign the informed consent form (ICF)
  3. Patients who are diagnosed with AML according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (refer to Appendix 1: WHO Classification of Acute Myeloid Leukemia)
  4. Patients who have a sufficient archival or fresh BM aspiration sample for the evaluation of relevant exploratory endpoint.

Note: Patients who do not have sufficient archival BM aspiration sample and refuse to repeat the procedure may be enrolled in the trial only after written confirmation by ASLAN 5. Part 1: Patients who are ineligible for standard treatment of AML including to the following conditions:

  • Patients who are ineligible for chemotherapy, and have exhausted any approved and available treatment options. More details on patients who are considered as ineligible or unfit for chemotherapy as per Ferrara et al, Leukemia, 2013 can be found in Appendix 4.
  • Patients who have from prior remission;
  • Patients who have failed to respond to prior therapy including chemotherapy, hypomethylating agents, and bone marrow transplantation.

    1. Part 2A: Patients who have relapsed or refractory AML to treatments including chemotherapy, hypomethylating agents, bone marrow transplantation, and other anti-leukemic agents
    • Relapsed patients who have bone marrow blasts ≥5%; or reappearance of blasts in the blood; or development of extramedullary disease after prior CR or CRi
    • Refractory patients who have no CR or CRi after 2 courses of intensive induction treatment 5. Part 2B: Older patients (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.

      1. Patients who have an performance status of ≤ 2 7. Patients with adequate renal and hepatic function, as defined below:
  • Estimated (eGFR) or (CrCl) (CrCl calculated by the Cockroft and Gault method) ≥ 40 ml/min/1.73 m2
  • Total , , and ALT ≤ 1.5 ×

Exclusion criteria

Exclusion Criteria:

  1. Patients who are diagnosed with de novo myeloid sarcoma without BM involvement
  2. Patients who are diagnosed with acute promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA)
  3. Patients who received any other standard or treatment for their leukemia within the last 7 days before starting the first dose of study drug, with the exception of leukapheresis and hydroxyurea
  4. Patients with unresolved serious toxicity (≥ 4.03 Grade 2) from prior administration of standard or investigational treatment for their leukemia
  5. Patients who have a positive test for (HIV), viral infection (patients with sustained viral response are not excluded), active viral infection (positive hepatitis B surface antigen [HBsAg]) with hepatitis B virus deoxyribonucleic acid (DNA) exceeding 2000 IU/ml
  6. Patients who have a known history of liver cirrhosis score B or C
  7. Patients who have any history of other unless in remission for more than 1 year (skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent is not exclusionary)
  8. Female patients who are pregnant or breast-feeding
  9. Patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment
  10. Patients with a history or presence of a condition which in the opinion of the Investigator could jeopardize the safety of the patient or the validity of the study results
  11. Patients who have been previously treated with ASLAN003
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Level 1

    Drug: ASLAN003

  • Experimental
    Part 1: Dose Level 2

    Drug: ASLAN003

  • Experimental
    Part 1: Dose Level 3

    Drug: ASLAN003

  • Experimental
    Part 1: Dose Level 4

    Drug: ASLAN003

  • Experimental
    Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine

    Drug: ASLAN003

  • Experimental
    Part 2:ASLAN003 at Optinum Dose Level & Azacitidine

    Drug: ASLAN003

Interventions

  • DrugFarudodstatStudies of FarudodstatFarudodstat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

06

What researchers measure

Primary outcomes

  1. Overall Complete Remission Rate

    Defined as the proportion of patients with a best response of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), defined in accordance with the IWG Response Criteria in AML from day 29. Treatment failure is defined as not achieving any response 4 months after study treatment. IWG Response Criteria in AML defines CR or CRi as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL))

    Time frame: 4 months after study treatment

  2. Number of Participants With Adverse Events

    Number of Participants with Adverse Events reported through 28 days post last study medication administration

    Time frame: Through 28 days post last study medication administration

  3. Safety Assessments

    Safety Assessments - Clinical laboratory test: Hematology and Chemistry

    Time frame: Through 28 days post last study medication administration

Secondary outcomes

  1. Relapse Free Survival

    Defined as the time the criteria for remission (CR or CRi) are first met until there is evidence of patient relapse, regardless of whether the patient is still taking study drug. Relapse is defined as: * The reappearance of leukemic blasts in the peripheral blood or \> 5% blasts in the bone marrow not attributable to any other cause; * The appearance of new dysplastic changes; * The reappearance of or development of cytologically proven extrameduallary disease; * The reappearance of a cytogenetic or molecular abnormality.

    Time frame: From 12 weeks post end of treatment (EOT) until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 24 months

  2. Clinical Benefit Rate

    Defined as the proportion of subjects with an AML IWG best response of CR, CRi or PR. IWG Response Criteria in AML defines CR, CRi or PR as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)) 3. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pre-treatment bone marrow blast percentage by at least 50 percent

    Time frame: 4 months after study treatment

  3. % Change From Baseline in BM Blasts at Day 29

    Percent Change from Baseline in BM Blasts at Day 29

    Time frame: Baseline and day 29

07

Results

Posted Jul 2, 2021

Participant flow

Participant flow — Overall Study
MilestonePart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
Started6666
Completed0000
Not completed6666
Withdrew: Withdrawal by subject2121
Withdrew: Disease recurrence0200
Withdrew: Lack of efficacy0301
Withdrew: Death1020
Withdrew: Physician decision0022
Withdrew: Disease progression (n=4), study closed by sponsor (n=1)3002

Outcome measures

PrimaryOverall Complete Remission Rate

Defined as the proportion of patients with a best response of complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), defined in accordance with the IWG Response Criteria in AML from day 29. Treatment failure is defined as not achieving any response 4 months after study treatment. IWG Response Criteria in AML defines CR or CRi as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL))

Time frame:
4 months after study treatment
Reported as:
Count of participants · Participants
Overall Complete Remission Rate
ParticipantsPart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
Responders0000
Treatment Failure2426
Non-evaluable4040
PrimaryNumber of Participants With Adverse Events

Number of Participants with Adverse Events reported through 28 days post last study medication administration

Time frame:
Through 28 days post last study medication administration
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
Number of Patients with Any TEAE5666
Number of Patients with Any TEAE related to study treatment3414
Number of Patients with Any TEAE CTCAE grade 3 or higher5566
Number of Patients with Any TEAE CTCAE grade 3 or higher related to study treatment2212
Number of Patients with Any TEAE with outcome of death0100
Number of Patients with Any TEAE with outcome of death related to study treatment0000
Number of Patients with Any serious TEAE3546
Number of Patients with Any serious TEAE related to study treatment0001
Number of Patients with Any TEAE leading to discontinuation of study therapy0010
Number of Patients with Any TEAE leading to discontinuation of study therapy related to treatment0000
PrimarySafety Assessments

Safety Assessments - Clinical laboratory test: Hematology and Chemistry

Time frame:
Through 28 days post last study medication administration
Reported as:
Number · participants
Safety Assessments
participantsPart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
Hematology - Abnormal white blood cell counts reported by Investigator as AEs of leukocytosis2330
Hematology - Abnormal/decreased hemoglobin values reported by Investigator as AEs of anaemia3122
Hematology - Abnormal neutrophil count reported by Investigator as AE of neutropenia0001
Hematology - Abnormal neutrophil counts reported by Investigator as AEs febrile neutropenia0102
Hematology - Abnormal/decreased platelet count reported by Investigator as AEs of thrombocytopenia2021
Chemistry - Abnormal serum potassium values reported by Investigator as AEs of hypokalaemia2321
Chemistry - Elevated levels of serum glucose reported by Investigator as AEs of hyperglycaemia1100
Chemistry - Abnormal blood creatinine reported by Investigator as AE of blood creatinine increased0010
SecondaryRelapse Free Survival

Defined as the time the criteria for remission (CR or CRi) are first met until there is evidence of patient relapse, regardless of whether the patient is still taking study drug. Relapse is defined as: * The reappearance of leukemic blasts in the peripheral blood or \> 5% blasts in the bone marrow not attributable to any other cause; * The appearance of new dysplastic changes; * The reappearance of or development of cytologically proven extrameduallary disease; * The reappearance of a cytogenetic or molecular abnormality.

Time frame:
From 12 weeks post end of treatment (EOT) until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 24 months

No measurements were reported for this outcome.

SecondaryClinical Benefit Rate

Defined as the proportion of subjects with an AML IWG best response of CR, CRi or PR. IWG Response Criteria in AML defines CR, CRi or PR as: 1. Complete remission (CR): Bone marrow blasts \<5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \>1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100,000/µL); independence of red cell transfusions 2. CR with incomplete recovery (CRi): All CR criteria except for residual neutropenia (\<1.0 x 109/L (1000/µL)) or thrombocytopenia (\<100 x 109/L (100,000/µL)) 3. Partial remission (PR): All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pre-treatment bone marrow blast percentage by at least 50 percent

Time frame:
4 months after study treatment

No measurements were reported for this outcome.

Secondary% Change From Baseline in BM Blasts at Day 29

Percent Change from Baseline in BM Blasts at Day 29

Time frame:
Baseline and day 29
Reported as:
Number · Percentage change
% Change From Baseline in BM Blasts at Day 29
Percentage changePart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
% Change From Baseline in BM Blasts at Day 29-34.43-8.33——

Adverse events

Collected over From the time of informed consent and until 28 days after the last administration of study drug, up to 24 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: ASLAN003 100mg QD6/6 (100%)3/6 (50%)3/6 (50%)
Part 1: ASLAN003 200mg QD6/6 (100%)5/6 (83.3%)4/6 (66.7%)
Part 1: ASLAN003 100mg BID6/6 (100%)4/6 (66.7%)1/6 (16.7%)
Part 1: ASLAN003 200mg BID3/6 (50%)6/6 (100%)4/6 (66.7%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
Febrile neutropeniaBlood and lymphatic system disorders0/61/60/63/6
PneumoniaInfections and infestations2/61/62/60/6
Respiratory syncytial virus infectionInfections and infestations1/61/60/60/6
Anal abscessInfections and infestations0/60/60/61/6
Lymph node abscessInfections and infestations0/60/60/61/6
Pathogen resistanceInfections and infestations1/60/60/60/6
Pulmonary sepsisInfections and infestations0/60/60/61/6
SepsisInfections and infestations0/60/61/60/6
Urinary tract infectionInfections and infestations0/60/61/60/6
ThrombocytopeniaBlood and lymphatic system disorders0/60/61/60/6
Most frequent other events
Most frequent other events
EventPart 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BID
LeukocytosisBlood and lymphatic system disorders2/61/61/60/6
AnaemiaBlood and lymphatic system disorders0/60/61/61/6
ThrombocytopeniaBlood and lymphatic system disorders1/60/60/61/6
Abdominal painGastrointestinal disorders1/61/60/60/6
NauseaGastrointestinal disorders1/60/60/61/6
Decreased appetiteMetabolism and nutrition disorders1/60/60/61/6
Rash maculo-papularSkin and subcutaneous tissue disorders1/61/60/60/6
EpistaxisRespiratory, thoracic and mediastinal disorders0/61/60/60/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
<=18 years00000
Between 18 and 65 years42028
>=65 years246416
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Female404210
Male262414
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Caucasian155415
Asian51118
Other00011
Not Hispanic or Latino666624
Region of Enrollment
Region of Enrollment(participants)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Singapore41117
Australia255517
Height
Height(CM)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Mean162.67 ± 8.189173.25 ± 7.640158.17 ± 9.827164.17 ± 7.627164.56 ± 9.604
Weight
Weight(KG)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Mean53.00 ± 13.54982.32 ± 11.21663.82 ± 16.55181.72 ± 21.24470.21 ± 9.637
BMI
BMI(kg/m^2)Part 1: ASLAN003 100mg QDPart 1: ASLAN003 200mg QDPart 1: ASLAN003 100mg BIDPart 1: ASLAN003 200mg BIDTotal
Mean19.855 ± 3.988327.368 ± 2.644625.065 ± 3.904230.553 ± 8.825425.710 ± 6.4119
08

Study locations

8 sites
  • 1 Site
    Louisville, Kentucky 40241, United States
  • 1 Site
    Albury, New South Wales, Australia
  • 3 Sites
    Darlinghurst, New South Wales, Australia
  • 1 Site
    Waratah, New South Wales, Australia
  • 1 Site
    Douglas, Queensland, Australia
  • 1 Site
    Adelaide, South Australia, Australia
  • 3 Sites
    Melbourne, Victoria, Australia
  • 3 Sites
    Singapore, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Sep 2019, 20 months.

Results were first posted in Jul 2021, 1 year 9 months after primary completion.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 20 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2018
First posted
Mar 1, 2018
StartActual
Jan 5, 2018
Primary completionActual
Sep 11, 2019
CompletionActual
Dec 13, 2019
Results first posted
Jul 2, 2021
Last update
Jul 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03451084
Lead sponsor
ASLAN Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 1, 2018
Start date
Jan 5, 2018
Primary completion
Sep 11, 2019
Completion
Dec 13, 2019
Results posted
Jul 2, 2021
Last update
Jul 6, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Farudodstat

Start the discussion